Therabron Therapeutics lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein (rhCC10), which has potential clinical applications in a variety of respiratory diseases including asthma, persistent sinusitis, severe influenza-like illness (ILI) and neonatal chronic respiratory morbidity (CRM) prevention. Therabron has also created a number of isoforms of naturally occurring analogues of native CC10 with the goal of evaluating their application in chronic respiratory disease (e.g. COPD) in an ambulatory setting.
A second secretoglobin protein product candidate, based on the naturally occurring SCGB3A2 protein (CG1011), has also completed non-clinical proof of concept studies in pulmonary fibrosis.

Two Phase 1 clinical trials have been completed with rhCC10 (CG100 and CG201). In addition to our current development programs, Therabron is developing next generation dosage forms including intravenous, intranasal and inhaled delivery routes.

  • The first trial was a Phase 1/2 study in premature infants unable to breathe sufficiently on their own at birth, with Respiratory Distress Syndrome (RDS), who were also at risk of developing Chronic Respiratory Morbidity (CRM). This clinical study evaluated the potential application of rhCC10 replacement (CG100) in the airways of intubated and mechanically ventilated premature newborns, assessing a variety of outcomes including: Possible acute anti-inflammatory effects as well as more long term outcomes relating to pulmonary-related hospital readmission and future respiratory well-being after a single dose soon after birth.
  • The second trial was a Phase 1/2 clinical study in healthy adult volunteers with seasonal allergies (CG201).

A Phase 2 Clinical Trial is ongoing to examine the use of CG100 in the airways of preterm infants at high risk for development of CRM post discharge from the Neonatal Intensive Care Unit (NICU).